We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > mRNA Vaccines

News List

Global Trial for COVID-19 Vaccine Begins at NYU Langone Health americanpharmaceuticalreview
August 04, 2020
The first U.S. patients are being dosed in a Phase 2/3 clinical trial testing whether a messenger RNA (mRNA) vaccine candidate can prevent infection with the virus that causes 2019 coronavirus disease (COVID-19).
European Investment Bank to provide BioNTech with up to €100 million in debt financing for COVID-19 vaccine development and manufacturing expresspharma
June 12, 2020
mRNA vaccines consist of genetic material, called messenger RNA, that provides instructions for a human cell to make a target protein, or immunogen, which activates the body’s immune response against the respective virus.

Previous page 1 2 Next page